Literature DB >> 22719002

Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome.

A Brunklaus1, R Ellis, E Reavey, G H Forbes, S M Zuberi.   

Abstract

Dravet syndrome is a severe infantile onset epileptic encephalopathy associated with mutations in the sodium channel alpha 1 subunit gene SCN1A. To date no large studies have systematically examined the prognostic, clinical and demographic features of the disease. We prospectively collected data on a UK cohort of individuals with Dravet syndrome during a 5-year study period and analysed demographic information based on UK population and birth figures. From structured referral data we examined a range of clinical characteristics including epilepsy phenotype, seizure precipitants, electroencephalography data, imaging studies, mutation class and response to medication. Predictors of developmental outcome were determined by logistic regression. We identified 241 cases with SCN1A mutation-positive Dravet syndrome, 207 of which were UK-based. The incidence of mutation-positive Dravet syndrome is at least 1:40 900 UK births. Clinical features predicting a worse developmental outcome included status epilepticus (odds ratio = 3.1; confidence interval = 1.5-6.3; P = 0.003), interictal electroencephalography abnormalities in the first year of life (odds ratio = 5.7; confidence interval = 1.9-16.8; P = 0.002) and motor disorder (odds ratio = 3.3; confidence interval = 1.7-6.4; P < 0.001). No significant effect was seen for seizure precipitants, magnetic resonance imaging abnormalities or mutation class (truncating versus missense). Abnormal magnetic resonance imaging was documented in 11% of cases, principally with findings of non-specific brain atrophy or hippocampal changes. Sodium valproate, benzodiazepines and topiramate were reported as being the most helpful medications at the time of referral. Aggravation of seizures was reported for carbamazepine and lamotrigine. The identification of factors influencing prognosis both aids counselling and encourages early, syndrome-specific therapy. Prevention of status epilepticus with regular medication and emergency protocols is important and may influence developmental outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22719002     DOI: 10.1093/brain/aws151

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  55 in total

Review 1.  Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders.

Authors:  Sacha B Nelson; Vera Valakh
Journal:  Neuron       Date:  2015-08-19       Impact factor: 17.173

2.  Genetics of Epilepsy in Clinical Practice.

Authors:  Samuel F Berkovic
Journal:  Epilepsy Curr       Date:  2015 Jul-Aug       Impact factor: 7.500

Review 3.  The Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Epilepsy in Paediatric Patients.

Authors:  Davide Mei; Elena Parrini; Carla Marini; Renzo Guerrini
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

4.  SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures.

Authors:  Katherine B Howell; Jacinta M McMahon; Gemma L Carvill; Dimira Tambunan; Mark T Mackay; Victoria Rodriguez-Casero; Richard Webster; Damian Clark; Jeremy L Freeman; Sophie Calvert; Heather E Olson; Simone Mandelstam; Annapurna Poduri; Heather C Mefford; A Simon Harvey; Ingrid E Scheffer
Journal:  Neurology       Date:  2015-08-19       Impact factor: 9.910

5.  Incidence of Dravet Syndrome in a US Population.

Authors:  Yvonne W Wu; Joseph Sullivan; Sharon S McDaniel; Miriam H Meisler; Eileen M Walsh; Sherian Xu Li; Michael W Kuzniewicz
Journal:  Pediatrics       Date:  2015-10-05       Impact factor: 7.124

6.  Modulation of Abnormal Sodium Channel Currents in Heart and Brain: Hope for SUDEP Prevention and Seizure Reduction.

Authors:  Lindsey B Gano; Heidi L Grabenstatter
Journal:  Epilepsy Curr       Date:  2017 Sep-Oct       Impact factor: 7.500

Review 7.  Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

Authors:  Julie Ziobro; Krista Eschbach; Joseph E Sullivan; Kelly G Knupp
Journal:  Curr Treat Options Neurol       Date:  2018-10-13       Impact factor: 3.598

8.  SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.

Authors:  Lihong Shi; Miaomiao Zhu; Huilan Li; Zhipeng Wen; Xiaoping Chen; Jia Luo; Cong Lin; Zanling Zhang
Journal:  Eur J Clin Pharmacol       Date:  2019-01-28       Impact factor: 2.953

9.  Variable epilepsy phenotypes associated with heterozygous mutation in the SCN9A gene: report of two cases.

Authors:  Cuiwei Yang; Yi Hua; Weiqin Zhang; Jialu Xu; Lu Xu; Feng Gao; Peifang Jiang
Journal:  Neurol Sci       Date:  2018-03-02       Impact factor: 3.307

10.  Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice.

Authors:  Akshitkumar M Mistry; Christopher H Thompson; Alison R Miller; Carlos G Vanoye; Alfred L George; Jennifer A Kearney
Journal:  Neurobiol Dis       Date:  2014-01-14       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.